3-Arm Non-Peptidyl Polymer Protein Complex for Serum Half-Life Extension
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for stabilizing protein medicines result in reduced biological activity or increased immune responses, and existing protein complexes fail to maintain high blood concentrations and serum half-life effectively, leading to frequent injections and economic inefficiencies.
Innovation Solution
A protein complex is created by linking a physiologically active polypeptide and a dimeric protein to a 3-arm non-peptidyl polymer via covalent bonds, using an immunoglobulin Fc domain as a carrier, which enhances stability and bioavailability while minimizing the loss of active polypeptide and simplifying purification processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional PEGylation methods are used to stabilize protein medicines, then stability and hydrolysis prevention are improved, but biological activity is reduced and immune responses are increased
Solution Approach 1:
The invention divides the PEG conjugation process into two separate steps: first conjugating PEG to the carrier protein (albumin or immunoglobulin), then conjugating the medicinally active polypeptide to the PEG-protein complex. This segmentation allows each conjugation step to be optimized independently, reducing steric hindrance and preserving the biological activity of the active polypeptide while maintaining stability benefits.
Solution Approach 2:
The PEG chain serves as an intermediary between the carrier protein and the active polypeptide. By using PEG as a flexible linker with controllable length and architecture, the invention mediates the interaction between the carrier and active ingredient, allowing the active polypeptide to maintain its conformation and activity while benefiting from the extended circulation time provided by PEGylation.
2Loss of substance
If PEG is grafted onto proteins to increase molecular weight and prevent renal loss, then renal loss is suppressed, but purification complexity increases
Solution Approach 1:
The invention segments the conjugation process into two distinct steps with intermediate purification. First, PEG is conjugated to the carrier protein and purified; then the active polypeptide is conjugated to the PEG-carrier complex. This segmentation simplifies each individual purification step compared to direct dual-conjugation, as each step deals with a single conjugation reaction rather than attempting to purify a complex mixture of multiple conjugation products.
Solution Approach 2:
The invention performs preliminary conjugation of PEG to the carrier protein before adding the active polypeptide. This preliminary action creates a defined intermediate product with known properties, making the subsequent conjugation step and final purification more straightforward. The intermediate PEG-carrier complex can be characterized and optimized independently before the final active ingredient is attached.
3Stability of the object's composition
If existing protein complexes are used to maintain blood concentrations, then some stability is achieved, but serum half-life extension is insufficient leading to frequent injections
Solution Approach 1:
The invention creates a composite structure combining three distinct components: a carrier protein (albumin or immunoglobulin), PEG chains, and the active medicinally active polypeptide. This composite material leverages the long circulation time of the carrier protein, the stabilizing and space-extending properties of PEG, and the biological activity of the active polypeptide, achieving synergistic extension of serum half-life that exceeds what any single component or simpler combination could provide.
Solution Approach 2:
The invention employs a nested structure where the active polypeptide is conjugated to PEG chains, which are in turn conjugated to the carrier protein. This nested arrangement (active polypeptide within PEG within carrier protein) allows each component to contribute its unique properties while being protected by the outer layers, resulting in extended circulation time and reduced clearance while maintaining activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The protein complex maintains high blood concentrations of the active polypeptide over a long period, significantly increasing serum half-life and production yield, reducing the frequency of injections, and minimizing immune responses, thus providing stable medicinal effects with improved bioavailability.
Implementation Method 1
a physiologically active polypeptide and a dimeric protein are linked to a non-peptidyl polymer having three functional ends (3-arm) via respective covalent bond
Data Source
AI summary
Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.